Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 105M | 20.2% |
| Gross Profit | -1.2M | 95.6% |
| Cost of Revenue | 106M | 6.6% |
| Operating expense | 143M | 8% |
| Net Income | -65M | 18.6% |
| EBITDA | -57M | 20.6% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 561M | 2.4% |
| Total Liabilities | 469M | 5.2% |
| Total Equity | 93M | 9.7% |
| Shares Outstanding | 48M | 1.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -19M | 38.1% |
| Cash from investing | -90,000 | 73.1% |
| Cash from financing | 30M | 111.5% |
EPS
Financial Highlights for Axsome Therapeutics in Q3 '24
Axsome Therapeutics reported a revenue of 105M, which is a 20.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -1.2M, marking a 95.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 106M, a -6.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 143M, showing a -8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -65M, showing a 18.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -57M, showing a 20.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Axsome Therapeutics with growth in revenue, gross profit, and net income.
